Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Change in Receivables (2018 - 2025)

Arcturus Therapeutics Holdings' Change in Receivables history spans 8 years, with the latest figure at -$2.4 million for Q4 2025.

  • For Q4 2025, Change in Receivables rose 90.9% year-over-year to -$2.4 million; the TTM value through Dec 2025 reached $1.6 million, up 105.66%, while the annual FY2025 figure was $1.6 million, 105.66% up from the prior year.
  • Change in Receivables reached -$2.4 million in Q4 2025 per ARCT's latest filing, up from -$9.3 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $89.7 million in Q1 2023 to a low of -$89.7 million in Q2 2023.
  • Average Change in Receivables over 5 years is $171950.0, with a median of -$133000.0 recorded in 2021.
  • The largest YoY upside for Change in Receivables was 27591.05% in 2023 against a maximum downside of 6110.8% in 2023.
  • A 5-year view of Change in Receivables shows it stood at $1.4 million in 2021, then plummeted by 46.75% to $720000.0 in 2022, then tumbled by 955.0% to -$6.2 million in 2023, then crashed by 326.01% to -$26.2 million in 2024, then soared by 90.9% to -$2.4 million in 2025.
  • Per Business Quant, the three most recent readings for ARCT's Change in Receivables are -$2.4 million (Q4 2025), -$9.3 million (Q3 2025), and $2.6 million (Q2 2025).